Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis

Alexandra Moran, Lorena Flor Ramos, Omar Picado, Fiorella Pendola, Danny Sleeman, Vikas Dudeja, Nipun Merchant, Danny Yakoub

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Hepatocellular carcinoma (HCC) has a recurrence rate of up to 70% in 5 years after resection, detrimentally lowering survival. The role of adjuvant therapy remains controversial; therefore, the aim of this study was to evaluate the disease-free and overall survival of patients with HCC, not candidates for transplantation, undergoing resection and adjuvant hepatic artery infusion therapy vs resection alone. Our meta-analysis showed that adjuvant HAIC improves overall and disease-free survival after resection, especially in tumors ≥7 cm.

Original languageEnglish (US)
Pages (from-to)455-463
Number of pages9
JournalJournal of surgical oncology
Volume119
Issue number4
DOIs
StatePublished - Mar 15 2019

Keywords

  • adjuvant hepatic artery infusion therapy (HAIT)
  • hepatocellular carcinoma (HCC)
  • resection

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this